Clinical trial
A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
NCT02610296 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
- Lead sponsor
- Quark Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 1, 2016
- Completion date
- January 8, 2019
- Enrollment
- 594 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.